Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suvorexant for Insomnia in Alzheimer's Disease
NCT02750306Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2016
- Primary completion
- Sep 2018
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of suvorexant in Insomnia, sponsored by Merck & Co.. Started May 2016; status: completed.
02
Drugs
suvorexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT02750306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02750306.